P15-05. Evaluation and recommendations on good clinical laboratory practice (GCLP) guidelines for phase I-III HIV vaccine clinical trials
Marcella Sarzotti‐Kelsoe(Duke Medical Center), Anita Simkins(AlphaVax (United States)), Naana Cleland(Henry M. Jackson Foundation), IR Rodriguez-Chavez(National Institutes of Health), Leila K. Needham(Duke University), Tony Tarragona-Fiol(Imperial College London), Josephine H. Cox(International AIDS Vaccine Initiative), Timothy A. Stiles, John Hural(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Thomas N. Denny(Duke University), Gwynneth Stevens(Development Bank of Southern Africa), Daniel A. Ozaki(Duke University)
Cited by 5
Related Papers
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
|Science|2022|1.2k
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis
|The Lancet|2008|708
Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine
|New England Journal of Medicine|2013|586
Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition
|New England Journal of Medicine|2021|557
Functions of IL-4 and Control of Its Expression
|Critical Reviews in Immunology|2017|354